Loading...
GRAIL Community
NasdaqGS:GRAL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
Community Investing Ideas
FDA Approval And NHS Studies Will Transform Cancer Detection
Key Takeaways Positive clinical results and expanding commercial adoption of Galleri position GRAIL for strong regulatory momentum, payer support, and accelerated, diversified revenue growth. Enhanced process scalability and disciplined cost control are improving margins and reducing losses, while global partnerships and demographic trends drive long-term opportunity.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$56.5
25.9% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
20.22% p.a.
Profit Margin
16.11%
Future PE
80.58x
Share price in 2028
US$68.58